Interferon-γ release assay for tuberculosis in patients with psoriasis treated with tumour necrosis factor antagonists:<i>in vivo</i>and<i>in vitro</i>analysis
Tóm tắt
Từ khóa
Tài liệu tham khảo
Christophers, 2001, Psoriasis - epidemiology and clinical spectrum, Clin Exp Dermatol, 26, 314, 10.1046/j.1365-2230.2001.00832.x
Solovic, 2010, The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement, Eur Respir J, 36, 1185, 10.1183/09031936.00028510
Cooper, 2008, The role of cytokines in the initiation, expansion, and control of cellular immunity to tuberculosis, Immunol Rev, 226, 191, 10.1111/j.1600-065X.2008.00702.x
Gardam, 2003, Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management, Lancet Infect Dis, 3, 148, 10.1016/S1473-3099(03)00545-0
Hernandez, 2008, Tuberculosis in the age of biologic therapy, J Am Acad Dermatol, 59, 363, 10.1016/j.jaad.2008.05.033
Doherty, 2008, National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents, J Am Acad Dermatol, 59, 209, 10.1016/j.jaad.2008.03.023
American Thoracic Society, 2000, Targeted tuberculin testing and treatment of latent tuberculosis infection, Am J Respir Crit Care Med, 161, S221, 10.1164/ajrccm.161.supplement_3.ats600
Tsiouri, 2009, Tuberculin skin test overestimates tuberculosis hypersensitivity in adult patients with psoriasis, Dermatology, 219, 119, 10.1159/000222431
Lalvani, 2007, Diagnosing tuberculosis infection in the 21st century: new tools to tackle an old enemy, Chest, 131, 1898, 10.1378/chest.06-2471
Pai, 2008, Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update, Ann Intern Med, 149, 177, 10.7326/0003-4819-149-3-200808050-00241
Laffitte, 2009, Tuberculosis screening in patients with psoriasis before antitumour necrosis factor therapy: comparison of an interferon-γ release assay vs. tuberculin skin test, Br J Dermatol, 161, 797, 10.1111/j.1365-2133.2009.09331.x
Desai, 2008, QuantiFERON-TB Gold testing for tuberculosis in psoriasis patients commencing anti-tumour necrosis factor alpha therapy, Br J Dermatol, 158, 1137, 10.1111/j.1365-2133.2008.08457.x
Chiu, 2011, Clinical experience of QuantiFERON-TB Gold testing in patients with psoriasis treated with tumour necrosis factor blockers in Taiwan, Br J Dermatol, 164, 553
Tavast, 2012, Immunosuppression adversely affects TST but not IGRAs in patients with psoriasis or inflammatory musculoskeletal diseases, Int J Rheumatol, 2012, 381929, 10.1155/2012/381929
Ramos, 2013, Negative effect of immunosuppressive therapy in the performance of the QuantiFERON Gold In-Tube test in patients with immune-mediated inflammatory diseases, Clin Exp Med, 13, 177, 10.1007/s10238-012-0192-7
Garcovich, 2012, Clinical applicability of Quantiferon-TB-Gold testing in psoriasis patients during long-term anti-TNF-α treatment: a prospective, observational study, J Eur Acad Dermatol Venereol, 26, 1572, 10.1111/j.1468-3083.2011.04220.x
Pai, 2009, T-cell assay conversions and reversions among household contacts of tuberculosis patients in rural India, Int J Tuberc Lung Dis, 13, 84
AbbVie Inc Humira prescribing information http://www.rxabbott.com/pdf/humira.pdf
Bang, 2004, Adalimumab: a review of its use in rheumatoid arthritis, BioDrugs, 18, 121, 10.2165/00063030-200418020-00005
Granneman, 2003, Pharmacokinetic/pharmacodynamic (PK/PD) relationships of adalimumab (HUMIRA, Abbott) in rheumatoid arthritis (RA) patients during phase II/III clinical trials, Arthritis Rheum, 48, S140
Sauzullo, 2010, Evaluation of QuantiFERON-TB Gold In-Tube in human immunodeficiency virus infection and in patient candidates for anti-tumor necrosis factor-alpha treatment, Int J Tuberc Lung Dis, 14, 834
Scrivo, 2012, Serial interferon-γ release assays for screening and monitoring of tuberculosis infection during treatment with biologic agents, Clin Rheumatol, 31, 1567, 10.1007/s10067-012-2049-6
Scrivo, 2013, Mycobacterial IFN-γ release variations during long-term treatment with tumor necrosis factor blockers: lack of correlation with clinical outcome, J Rheumatol, 40, 157, 10.3899/jrheum.120688
Ledingham, 2005, Update on the British Society for Rheumatology guidelines for prescribing TNFα blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001), Rheumatology, 44, 157, 10.1093/rheumatology/keh464
Leyten, 2007, Effect of tuberculin skin testing on a Mycobacterium tuberculosis-specific interferon-gamma assay, Eur Respir J, 29, 1212, 10.1183/09031936.00117506
Sauzullo, 2011, Influence of previous tuberculin skin test on serial IFN-γ release assays, Tuberculosis (Edinb), 91, 322, 10.1016/j.tube.2011.05.004
Katiyar, 2008, Use of the QuantiFERON-TB Gold In-Tube test to monitor treatment efficacy in active pulmonary tuberculosis, Int J Tuberc Lung Dis, 12, 1146
Carrara, 2004, Use of a T cell-based assay for monitoring efficacy of antituberculosis therapy, Clin Infect Dis, 38, 754, 10.1086/381754
Sauzullo, 2009, In vivo and in vitro effects of antituberculosis treatment on mycobacterial interferon-gamma T cell response, PLoS One, 4, e5187, 10.1371/journal.pone.0005187
Pai, 2006, Persistently elevated T cell interferon-gamma responses after treatment for latent tuberculosis infection among health care workers in India: a preliminary report, J Occup Med Toxicol, 1, 7, 10.1186/1745-6673-1-7
Higuchi, 2008, Interferon-gamma responses after isoniazid chemotherapy for latent tuberculosis, Respirology, 13, 468, 10.1111/j.1440-1843.2008.01244.x
Marehbian, 2009, Adverse events associated with common therapy regimens for moderate-to-severe Crohn's disease, Am J Gastroenterol, 104, 2524, 10.1038/ajg.2009.322
Rutgeers, 2006, Review article: infliximab therapy for inflammatory bowel disease - seven years on, Aliment Pharmacol Ther, 3, 451, 10.1111/j.1365-2036.2006.02786.x
Chen, 2012, Biphasic emergence of active tuberculosis in rheumatoid arthritis patients receiving TNFα inhibitors: the utility of IFNγ assay, Ann Rheum Dis, 71, 231, 10.1136/annrheumdis-2011-200489
Choi, 2008, The effect of previous tuberculin skin test on the follow-up examination of whole-blood interferon-gamma assay in the screening for latent tuberculosis infection, Chest, 133, 1415, 10.1378/chest.07-2193
Hill, 2007, Using ELISPOT to expose false positive skin test conversion in tuberculosis contacts, PLoS One, 2, e183, 10.1371/journal.pone.0000183
Naseer, 2007, Evidence for boosting Mycobacterium tuberculosis-specific IFN-gamma responses at 6 weeks following tuberculin skin testing, Eur Respir J, 29, 1282, 10.1183/09031936.00017807
Hill, 2007, Longitudinal assessment of an ELISPOT test for Mycobacterium tuberculosis infection, PLOS Med, 4, e192, 10.1371/journal.pmed.0040192
Ewer, 2006, Dynamic antigen-specific T-cell responses after point-source exposure to Mycobacterium tuberculosis, Am J Respir Crit Care Med, 174, 831, 10.1164/rccm.200511-1783OC
Pai, 2006, Serial testing of health care workers for tuberculosis using interferon-gamma assay, Am J Respir Crit Care Med, 174, 349, 10.1164/rccm.200604-472OC
Perry, 2008, Reproducibility of QuantiFERON-TB gold in-tube assay, Clin Vaccine Immunol, 15, 425, 10.1128/CVI.00398-07
Veerapathran, 2008, T-cell assays for tuberculosis infection: deriving cut-offs for conversions using reproducibility data, PLoS One, 3, e1850, 10.1371/journal.pone.0001850
Daley, 2013, A summary of meeting proceedings on addressing variability around the cut point in serial interferon-γ release assay testing, Infect Control Hosp Epidemiol, 34, 625, 10.1086/670635
Hamdi, 2006, Inhibition of antituberculosis T-lymphocyte function with tumour necrosis factor antagonists, Arthritis Res Ther, 8, R114, 10.1186/ar1994